CYP2C19 and gastroesophageal reflux disease: Furthermore, indirect evidence of the relevance of gastric acid is that vonoprazan, a more powerful PPI that acts independently of CYP2C19, improves the symptoms of many patients with GERD that is refractory to conventional PPIs [17, 40].